These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 11878047)

  • 1. Monoclonal antibodies conjugated with radioisotopes for the treatment of Non-Hodgkin's lymphoma.
    Bush S
    Semin Oncol Nurs; 2002 Feb; 18(1 Suppl 1):16-21. PubMed ID: 11878047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.
    Hendrix CS; de Leon C; Dillman RO
    Clin J Oncol Nurs; 2002; 6(3):144-8. PubMed ID: 11998607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunotherapy for non-Hodgkin's lymphoma.
    Liebenguth P; Vogt Temple S
    Semin Oncol Nurs; 2006 Nov; 22(4):257-66. PubMed ID: 17095402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).
    Bischof Delaloye A
    Leuk Lymphoma; 2003; 44 Suppl 4():S29-36. PubMed ID: 15154740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
    Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
    J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    Meredith RF
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S23-9. PubMed ID: 16979435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Riley MB; Gordon LI
    Semin Oncol Nurs; 2004 Feb; 20(1 Suppl 1):8-13. PubMed ID: 15160856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation safety with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy.
    Hendrix C
    Semin Oncol Nurs; 2004 Feb; 20(1 Suppl 1):14-9. PubMed ID: 15160857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
    DeNardo GL; DeNardo SJ; O'Donnell RT; Kroger LA; Kukis DL; Meares CF; Goldstein DS; Shen S
    Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Logistics of therapy with the ibritumomab tiuxetan regimen.
    Meredith RF
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S35-8. PubMed ID: 16979437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
    Gordon LI; Witzig TE; Wiseman GA; Flinn IW; Spies SS; Silverman DH; Emmanouilides C; Cripe L; Saleh M; Czuczman MS; Olejnik T; White CA; Grillo-López AJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):87-92. PubMed ID: 11842394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma.
    Schaefer-Cutillo J; Friedberg JW
    Semin Hematol; 2008 Apr; 45(2):110-7. PubMed ID: 18381106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Indications for radioimmunotherapy for patients with non-Hodgkin's lymphoma].
    Frølund UC; Hansen PB
    Ugeskr Laeger; 2011 May; 173(20):1417-21. PubMed ID: 21586245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rationale for and background of radioimmunotherapy: an emerging therapy for B-cell non-Hodgkin's lymphoma.
    Riley MB; Byar K
    Semin Oncol Nurs; 2004 Feb; 20(1 Suppl 1):1-7. PubMed ID: 15160855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy of non-Hodgkin's lymphoma: molecular targeting and novel agents.
    Pauwels EK; Erba P
    Drug News Perspect; 2007 Mar; 20(2):87-93. PubMed ID: 17440631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation safety guidelines for radioimmunotherapy with yttrium 90 ibritumomab tiuxetan.
    Hendrix C
    Clin J Oncol Nurs; 2004 Feb; 8(1):31-4. PubMed ID: 14983760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma.
    Multani P
    Int J Hematol; 2002 Dec; 76(5):401-10. PubMed ID: 12512834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.